Product Search

An increase in public funding for research and a heightened interest among drug developers suggest that a breakthrough in autism spectrum disorder (ASD)...

“Progress” aptly describes the expanding field of genetic testing. The field is more than finding linkages of genes with diseases: it encompasses technologies...

2008 came to a close amid political transition in the world’s largest pharmaceutical market and economic upheaval in all of the world’s markets. Our review of...

No Bear Stearns, no Lehman Brothers, no Chrysler, no humiliating hat-in-hand audiences with Congress. The biopharma industry has not seen one of its leaders...

Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications, 28% 12-month prevalence that yields large patient...

One of the fastest-growing segments of molecular diagnostics is nucleic acid testing (NAT). NAT is central to the life sciences industry, to improved...

Neurological disorders will impose a growing social and financial burden on the major pharmaceutical markets as the elderly population in these countries...

The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government has recently announced $1.1 billion in funding for...

The second quarter of 2009 saw steady progress toward healthcare reform in the United States and action in several of the world’s other major pharmaceutical...

Generalized anxiety disorder (GAD) is a prevalent psychiatric disorder in the major pharmaceutical markets, and drug therapy is considered the most effective...

Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and damage of neurons associated with neurodegenerative...